Targeting the NANOG/HDAC1 axis reverses resistance to PD-1 blockade by reinvigorating the antitumor immunity cycle

Targeting the NANOG/HDAC1 axis reverses resistance to PD-1 blockade by reinvigorating the antitumor immunity cycle

Immune checkpoint blockade (ICB) therapy has shifted the paradigm for cancer treatment. However, the majority of patients lack effective responses because of the emergence of immune-refractory tumors that disrupt the amplification of antitumor immunity. Therefore, the identification of clinically av...

Full description

Bibliographic Details
Main Authors:	Se Jin Oh, Hyo-Jung Lee, Kwon-Ho Song, Suyeon Kim, Eunho Cho, Jaeyoon Lee, Marcus W. Bosenberg, Tae Woo Kim
Format:	Article
Language:	English
Published:	American Society for Clinical Investigation 2022-03-01
Series:	The Journal of Clinical Investigation
Subjects:	Oncology Therapeutics
Online Access:	https://doi.org/10.1172/JCI147908

Similar Items

579-A Targeting the NANOG-CRY1 axis sensitizes immunotherapy-refractory tumors and enhances efficacy of T cell-based immunotherapy by reinvigorating the anti-tumor immunity cycle
by: Tae Woo Kim, et al.
Published: (2023-11-01)

PD-1 Immune Checkpoint Blockade and PSGL-1 Inhibition Synergize to Reinvigorate Exhausted T Cells
by: Karla M. Viramontes, et al.
Published: (2022-06-01)

PPT1 inhibition enhances the antitumor activity of anti–PD-1 antibody in melanoma
by: Gaurav Sharma, et al.
Published: (2020-09-01)

Lenvatinib or anti-VEGF in combination with anti–PD-1 differentially augments antitumor activity in melanoma
by: Thuy T. Tran, et al.
Published: (2023-04-01)

Aurora A kinase inhibition compromises its antitumor efficacy by elevating PD-L1 expression
by: Xiaobo Wang, et al.
Published: (2023-05-01)

Tele-Oral Oncology: Reinvigorating Telemedicine in Oral Cancer Care
by: Zaid H. Khoury, et al.
Published: (2020-01-01)

Bronchoalveolar lavage fluid reveals factors contributing to the efficacy of PD-1 blockade in lung cancer
by: Kentaro Masuhiro, et al.
Published: (2022-05-01)

MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment
by: Douglas D. Fang, et al.
Published: (2019-11-01)

Targeting TREM1 augments antitumor T cell immunity by inhibiting myeloid-derived suppressor cells and restraining anti–PD-1 resistance
by: Ashwin Ajith, et al.
Published: (2023-11-01)

Decitabine priming increases anti–PD-1 antitumor efficacy by promoting CD8+ progenitor exhausted T cell expansion in tumor models
by: Xiang Li, et al.
Published: (2023-04-01)

Distinct Dynamics of Migratory Response to PD-1 and CTLA-4 Blockade Reveals New Mechanistic Insights for Potential T-Cell Reinvigoration following Immune Checkpoint Blockade
by: Fateme Safaeifard, et al.
Published: (2022-11-01)

845 ABL503 (TJ-L14B), PD-L1×4–1BB bispecific antibody, reinvigorates exhausted tumor-infiltrating CD8+ T cells and synergizes with PD-1 blockade
by: Seung Hyuck Jeon, et al.
Published: (2023-11-01)

Role of HR23B, HDAC6 and Myd88 and their interplay in response to HDAC inhibitor treatment
by: New, M
Published: (2014)

Potent antitumor effects of cell-penetrating peptides targeting STAT3 axis
by: Maryam Aftabizadeh, et al.
Published: (2021-01-01)

Nonredundant, isoform-specific roles of HDAC1 in glioma stem cells
by: Costanza Lo Cascio, et al.
Published: (2021-09-01)

Investigation of the effects of IGF-1 receptor blockade on chemoresistance of advanced melanoma
by: Ramcharan, R, et al.
Published: (2014)

Frequent amplification of HDAC genes and efficacy of HDAC inhibitor chidamide and PD-1 blockade combination in soft tissue sarcoma
by: Ze-Xian Liu, et al.
Published: (2021-02-01)

Blockade of the immunosuppressive KIR2DL5/PVR pathway elicits potent human NK cell–mediated antitumor immunity
by: Xiaoxin Ren, et al.
Published: (2022-11-01)

PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
by: Zijun Y. Xu-Monette, et al.
Published: (2017-12-01)

DNASE1L3 enhances antitumor immunity and suppresses tumor progression in colon cancer
by: Wenling Li, et al.
Published: (2023-09-01)

Immunomodulation of HDAC Inhibitor Entinostat Potentiates the Anticancer Effects of Radiation and PD-1 Blockade in the Murine Lewis Lung Carcinoma Model
by: Yeeun Kim, et al.
Published: (2022-12-01)

TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM
by: Alice L. Hung, et al.
Published: (2018-08-01)

A bispecific anti-PD-1 and PD-L1 antibody induces PD-1 cleavage and provides enhanced anti-tumor activity
by: Diana I. Albu, et al.
Published: (2024-12-01)

Resistance to anti-PD-1/anti-PD-L1: galectin-3 inhibition with GB1211 reverses galectin-3-induced blockade of pembrolizumab and atezolizumab binding to PD-1/PD-L1
by: Joseph Mabbitt, et al.
Published: (2023-08-01)

Hyperprogression of cutaneous T cell lymphoma after anti–PD-1 treatment
by: Yumei Gao, et al.
Published: (2023-02-01)

NANOG confers resistance to complement-dependent cytotoxicity in immune-edited tumor cells through up-regulating CD59
by: Sung Wook Son, et al.
Published: (2022-05-01)

PD-1/PD-L1 Checkpoint Inhibitors Are Active in the Chicken Embryo Model and Show Antitumor Efficacy <i>In Ovo</i>
by: Yan Wang, et al.
Published: (2022-06-01)

Tim-3 mediates T cell trogocytosis to limit antitumor immunity
by: Ornella Pagliano, et al.
Published: (2022-05-01)

Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
by: Hyun Tae Lee, et al.
Published: (2017-07-01)

Single-cell transcriptomics reveals the effect of PD-L1/TGF-β blockade on the tumor microenvironment
by: Yoong Wearn Lim, et al.
Published: (2021-05-01)

Successful Treatment of Myasthenia Gravis Following PD-1/CTLA-4 Combination Checkpoint Blockade in a Patient With Metastatic Melanoma
by: Jan-Michael Werner, et al.
Published: (2019-02-01)

SCCA1/SERPINB3 suppresses antitumor immunity and blunts therapy-induced T cell responses via STAT-dependent chemokine production
by: Liyun Chen, et al.
Published: (2023-08-01)

Histone methyltransferase WHSC1 loss dampens MHC-I antigen presentation pathway to impair IFN-γ–stimulated antitumor immunity
by: Jiale Ren, et al.
Published: (2022-04-01)

Single-cell characterization of anti–LAG-3 and anti–PD-1 combination treatment in patients with melanoma
by: Jani Huuhtanen, et al.
Published: (2023-03-01)

Peptide self-assembled nanomedicine induces antitumor immunity by blocking the PD-1/PD-L1 axis
by: Tao Huang, et al.
Published: (2022-12-01)

Beyond PD(L)-1 Blockade in Microsatellite-Instable Cancers: Current Landscape of Immune Co-Inhibitory Receptor Targeting
by: Edoardo Crimini, et al.
Published: (2024-01-01)

Combining an adenovirus encoding human endostatin and PD‐1 blockade enhanced antitumor immune activity
by: Yaomei Tian, et al.
Published: (2023-03-01)

Pirfenidone facilitates immune infiltration and enhances the antitumor efficacy of PD-L1 blockade in mice
by: Wan Qin, et al.
Published: (2020-01-01)

Irreversible electroporation combined with chemotherapy and PD-1/PD-L1 blockade enhanced antitumor immunity for locally advanced pancreatic cancer
by: Yangyang Ma, et al.
Published: (2023-08-01)

Antitumor Effect of Korean Red Ginseng through Blockade of PD-1/PD-L1 Interaction in a Humanized PD-L1 Knock-In MC38 Cancer Mouse Model
by: Eun-Ji Lee, et al.
Published: (2023-01-01)